Company intelligence / Profile preview

Xenometrix

Allschwil, Basel-Landschaft, Switzerlandxenometrix.ch ↗

Ownership: Private
Development stage: Commercial

Overview

Xenometrix AG is a leading provider of miniaturized mutagenicity and cytotoxicity assay kits—most notably advanced versions of the Ames test—and service analytics. Their platforms are widely used by pharmaceutical, chemical, cosmetic industries and environmental authorities worldwide to assess genotoxicity and endocrine disruption potential. The company does not develop drugs but enables preclinical safety screening with validated high-throughput assays that reduce animal use and waste while increasing reproducibility.

Therapeutic areas: Other
Modalities: Small molecule screening/testingEnvironmental sample testingEndocrine disruptor detection
Industry: Drug Discovery Services

Partnerships

Global distributor networkCustomer network (pharmaceutical/chemical/cosmetic companies)

Beyond the preview

Go deeper on Xenometrix.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenometrix.

Explore the full profile